New drug combo aims to shrink pancreatic tumors before surgery
NCT ID NCT05209074
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tests whether adding a targeted drug called ivosidenib to standard chemotherapy can help shrink pancreatic tumors before surgery. About 16 people with resectable pancreatic cancer that has a specific gene mutation (IDH1) will receive the drug combination for up to 90 days, then undergo surgery. The main goal is to find a safe dose and see how well the tumors respond.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ivosidenib (a drug targeting a specific gene mutation) combined with chemotherapy (mFOLFIRINOX)
What this could lead to
If successful, this could point toward a more effective pre-surgery treatment for a subset of pancreatic cancer patients with an IDH1 mutation.
What could go wrong
This is a very early, small Phase 1 trial with only 16 participants, so results may not apply broadly. The drug combination may cause significant side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States